Created at	Source	Raw Value	Validated value
June 25, 2024, noon	usa	* patients with uncontrolled systemic fungal and bacterial infections * patients with latent tuberculosis * patients with known hypersensitivity to tocilizumab or any component of the formulation * concurrent initiation of steroid therapy is not allowed * patients with uncrontroled malignant disease, with a life expectancy of 3 months or less	* patients with uncontrolled systemic fungal and bacterial infections * patients with latent tuberculosis * patients with known hypersensitivity to tocilizumab or any component of the formulation * concurrent initiation of steroid therapy is not allowed * patients with uncrontroled malignant disease, with a life expectancy of 3 months or less
Oct. 26, 2020, 11:31 p.m.	usa	- patients with uncontrolled systemic fungal and bacterial infections - patients with latent tuberculosis - patients with known hypersensitivity to tocilizumab or any component of the formulation - concurrent initiation of steroid therapy is not allowed - patients with uncrontroled malignant disease, with a life expectancy of 3 months or less	- patients with uncontrolled systemic fungal and bacterial infections - patients with latent tuberculosis - patients with known hypersensitivity to tocilizumab or any component of the formulation - concurrent initiation of steroid therapy is not allowed - patients with uncrontroled malignant disease, with a life expectancy of 3 months or less